Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 568 | $46.48 | $26,400.64 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,872 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionRestricted Stock Units · Derivative | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,789 Underlying: Common Stock · 2,262 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,310 | $46.48 | $60,888.80 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,366.99 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:15 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002368 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,676.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:18 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002157 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,846 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:18 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,069 | $47.29 | $50,553.01 |
DisclosureSEC source: 0001225208-23-002157 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,414.99 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:18 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002157 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,483.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 548 | $47.29 | $25,914.92 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,659 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002156 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002155 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 739 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 340 | $47.29 | $16,078.60 |
DisclosureSEC source: 0001225208-23-002155 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,001 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002155 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002154 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,031 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 622 | $47.29 | $29,414.38 |
DisclosureSEC source: 0001225208-23-002154 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,888 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002154 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionDeferred Stock Units · Derivative | 4,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002152 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,615 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 2,488 | $47.29 | $117,657.52 |
DisclosureSEC source: 0001225208-23-002152 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,954 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002152 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002153 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,457 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 8,186 | $47.29 | $387,115.94 |
DisclosureSEC source: 0001225208-23-002153 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,813,151 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002153 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,821,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002151 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Carruthers WendyEVP, Human Resources
|
Tax withholdingCommon Stock | 737 | $47.29 | $34,852.73 |
DisclosureSEC source: 0001225208-23-002151 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,609 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:17 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002151 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionDeferred Stock Units · Derivative | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 923 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 323 | $47.29 | $15,274.67 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,602 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionDeferred Stock Units · Derivative | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002150 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,846 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 819 | $47.29 | $38,730.51 |
DisclosureSEC source: 0001225208-23-002150 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,419 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002150 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,572 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · derivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,572 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,153 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 7,572 | $47.14 | $356,927.42 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,316 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.993 to $47.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,219 | $47.29 | $57,646.51 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,888 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 7,572 | $7.39 | $55,957.08 |
DisclosureSEC source: 0001225208-23-002148 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2023 Filed Feb 21, 2023 21:08 UTC Amendment |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 2,278 | $47.29 | $107,726.62 |
DisclosureSEC source: 0001225208-23-002350 · doc4a.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,164 F1 · kind: This Form 4 is being amended to correct the number of shares withheld for taxes. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 24,765 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002042 · doc4.xml · derivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,765 Underlying: Common Stock · 24,765 shares Expires 2033-02-14 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantPerformance Share Units · Derivative | 7,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002042 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,946 Underlying: Common Stock · 7,946 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantRestricted Stock Units · Derivative | 9,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002041 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,517 Underlying: Common Stock · 9,517 shares Expires 2027-02-14 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Monson JonathanSVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 12,702 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002039 · doc4.xml · derivative · entry 2 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,702 Underlying: Common Stock · 12,702 shares Expires 2033-02-14 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Monson JonathanSVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 4,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002039 · doc4.xml · derivative · entry 1 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,230 Underlying: Common Stock · 4,230 shares Expires 2027-02-14 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantStock Option (Right to Buy) · Derivative | 22,014 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 4 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,014 Underlying: Common Stock · 22,014 shares Expires 2033-02-14 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantRestricted Stock Units · Derivative | 8,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,460 Underlying: Common Stock · 8,460 shares Expires 2027-02-14 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:45 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantPerformance Share Units · Derivative | 4,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002040 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,469 Underlying: Common Stock · 4,469 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:44 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 28,893 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002038 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,893 Underlying: Common Stock · 28,893 shares Expires 2033-02-14 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:44 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantRestricted Stock Units · Derivative | 11,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002038 · doc4.xml · derivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,104 Underlying: Common Stock · 11,104 shares Expires 2027-02-14 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:44 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantPerformance Share Units · Derivative | 10,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002038 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,430 Underlying: Common Stock · 10,430 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.